Sector News

Categories

Borderless Insights

Image
Ditch Your CV Biases: Finding Your Next Leader Demands a Storyteller’s Curiosity
Image
Career 2.0: Mid-Career Transition for the Over-50 Executive
Image
How can we really achieve gender equity in the C-Suite?

Valeant’s still in the deal hunt, but it can grow 10%-plus without them, CEO says

January 8, 2015
Life sciences
In the wake of Valeant’s Allergan bid failure, rumors swirled that the serial buyer would swear off its modus operandi for a while to focus on cutting down debt. But according to CEO J. Michael Pearson, those who expect Valeant to stray from its dealmaking ways have another thing coming.
 
The company’s “business development activities will remain the priority for 2015,” he told investors on a conference call Thursday, noting that the Canadian pharma expects a “steady flow of small and medium-sized deals” to continue over the course of the year. It’s continuing to evaluate larger transactions, too, but the timing of those “remains difficult to predict.”
 
Still, the Quebec-based pharma is doing its best to convince its shareholders–and potential takeover targets–that it’s self-sufficient. After a months-long attack from Allergan on its business model and comparatively paltry R&D activities, Pearson Thursday touted Valeant’s pipeline and organic growth, which he expects to see climb to 10% to 12% this year.
 
Revenue from new products–which Pearson plans to promote aggressively–should help Valeant generate a top-line haul ranging between $9.2 billion and $9.3 billion, the pharma figures. Cash earnings will hit between $10.10 and $10.40 per share, it predicts.
 
In the meantime, Pearson’s putting his money where his mouth is. He’s extended his contract by 5 years, but going forward, he’ll do away with his base salary. His compensation will be wholly dependent on the company’s stock performance.
 
By Carly Helfand
 

comments closed

Related News

September 22, 2023

Novo Holdings acquires biopharma company Paratek for $462m

Life sciences

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

Read more
September 22, 2023

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

Read more
September 22, 2023

Lonza-CEO Ruffieux to leave Swiss CDMO

Life sciences

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.

Read more
More news

How can we help you?

We're easy to reach